Showing 3171-3180 of 4368 results for "".
- Dermatological Advocates Present Dr. Adam Friedman with Advocacy Leadership Awardhttps://practicaldermatology.com/news/dermatological-advocates-present-dr-adam-friedman-with-advocacy-leadership-award/2460738/The Derma Care Access Network (DCAN), a national non-profit coalition advocating for patient access to optimal dermatological care, is recognizing Adam Friedman, MD with its inaugural Advocacy Leadership Award for his work as a passionate advocate and
- Study Documents Arm, Skin Rashes After COVID-19 Vaccinationshttps://practicaldermatology.com/news/study-documents-covid-vaccine-arm-skin-rashes-after-covid-19-vaccinations/2460737/As COVID-19 vaccination ramps up globally, new research in the Journal of the American Academy of Dermatology demonstrates the wide variety of skin rashes, including full-body rashes, observed after COVID
- FDA Grants 510(k) Clearance to Chemence Medical’s Exofin Fusion Redesignhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-chemence-medicals-exofin-fusion-redesign/2460736/The U.S. Federal Drug Administration gave its nod to Chemence Medical’s redesigned exofin fusion skin closure system. Exofin fusion combines a self-adhering flexible mesh strip and a fast-curing 2-octyl cyanoacrylate topical adhesive to close and seal incisions while forming an im
- Journey Medical to Acquire Dermira's Qbrexzahttps://practicaldermatology.com/news/journey-medical-to-acquire-dermiras-qbrexza/2460731/Journey Medical Corporation, a partner company of Fortress Biotech, Inc., has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. The transaction is expected to close early in the secon
- Verrica CMO Dr. Gary Goldenberg Elected to Membership in the American Dermatological Associationhttps://practicaldermatology.com/news/verrica-cmo-dr-gary-goldenberg-elected-to-membership-in-the-american-dermatological-association/2460728/Gary Goldenberg, MD has been elected as an active member into the American Dermatological Association (ADA). Dr. Goldenberg is Verrica’s Chief Medical Officer. “We congratulate Gary on his well-deserved election into the ADA, one of the highest honors in d
- Dermata Doses First Patient in Phase 1b Trial of Topical DMT310 for Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/dermata-doses-first-patient-in-phase-1b-trial-of-topical-dmt310-for-mild-to-moderate-psoriasis/2460726/Dermata Therapeutics, Inc. dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis. DMT310 is currently being investigated to treat multiple inflammatory skin diseases. It consists of a once-weekly topical treatment with both mech
- Kenneth J. Tomecki, MD, FAAD is New President of the AADhttps://practicaldermatology.com/news/kenneth-j-tomecki-md-faad-is-new-president-of-the-aad/2460723/Kenneth J. Tomecki, MD, FAAD is now president of the American Academy of Dermatology (AAD). During his one-year term, Dr. Tomecki will lead the world’s largest dermatologic society, representing more than 20,000 physicians specializing
- Two-Year Data Confirm Benefits, Safety of Tremfya in PsA and PsOhttps://practicaldermatology.com/news/two-year-data-confirm-benefits-safety-of-tremfya-is-psa-and-pso/2460722/Long-term data from the Phase 3 DISCOVER-2 study show continued benefit for Tremfya (guselkumab) for up to two years in adults with active psoriatic arthritis. Previous data demonstrated skin clearance, joint symptom relief, and safety for Tremfya through 24 weeks and one year (Week 52) in a
- Study: Clear Masks Improve Communication with Patientshttps://practicaldermatology.com/news/study-clear-masks-improve-communication-with-patients/2460716/Seeing really is believing. New research shows that doctors who wear transparent face masks greatly improve communication with patients compared to doctors whose faces are blocked by a standard face masks. What’s more, providers who wore the ClearMask are also perc
- Dr. Roy Geronemus Named CEO of NavaDermhttps://practicaldermatology.com/news/dr-roy-geronemus-named-ceo-of-navaderm/2460715/New York City dermatologist Roy Geronemus, MD is NavaDerm Partners’ new Chief Executive Officer. Dr. Geronemus graduated from Harvard University and pursued his medical education at the University of Miami School of Medicine where he is a member of the school's Alumni Hal